Photodynamic therapy with 3-(1'-hexyloxyethyl) pyropheophorbide-a for early-stage cancer of the larynx: Phase Ib study.
Photodynamic therapy with 3-(1'-hexyloxyethyl) pyropheophorbide-a for early-stage cancer of the larynx: Phase Ib study.
复制标题
DOI：
10.1002/hed.24003
复制
发表时间：
2016-04
影响因子：
2.9
通讯作者：
Henderson, Barbara W.
中科院分区：
文献类型：
--
作者：
Shafirstein, Gal;Rigual, Nestor R.;Arshad, Hassan;Cooper, Michele T.;Bellnier, David A.;Wilding, Gregory;Tan, Wei;Merzianu, Mihai;Henderson, Barbara W.
本研究旨在报道3-(1‘-己氧基乙基)焦脱镁叶绿酸-a(HPPH)介导的光动力疗法(PDT)治疗早期喉部疾病的安全性，并提供有关治疗反应的初步信息。HPPH-PDT在高危异型增生、原位癌和T1喉鳞状细胞癌(SCC)患者中的单机构、Ib期、开放标记、非对照研究。主要结果是安全性和最大耐受量(MTD)，次要结果是有效。治疗29例患者30处皮损。最常见的不良事件(AE)是一过性声音嘶哑。严重水肿，需要气管切开，是最严重的AE，2例患者在治疗后几个小时内发生。MTD为100J/cm2。T1SCC患者在MTD时对HPPH-PDT的完全缓解率似乎很好(82%)。HPPH-PDT可安全用于治疗早期喉癌，具有潜在的疗效。©2015作者Head&Neck由Wiley期刊出版公司Head Neck 38：E377-E383,2016
The purpose of this study was for us to report results regarding the safety of 3‐(1′‐hexyloxyethyl) pyropheophorbide‐a (HPPH) mediated photodynamic therapy (PDT) in early laryngeal disease, and offer preliminary information on treatment responses. A single‐institution, phase Ib, open label, noncomparative study of HPPH‐PDT in patients with high‐risk dysplasia, carcinoma in situ, and T1 squamous cell carcinoma (SCC) of the larynx. The primary outcomes were safety and maximum tolerated dose (MTD), and the secondary outcome was response. Twenty‐nine patients and 30 lesions were treated. The most common adverse event (AE) was transient hoarseness of voice. Severe edema, requiring tracheostomy, was the most serious AE, which occurred in 2 patients within several hours of therapy. The MTD was 100 J/cm2. Patients with T1 SCC seemed to have good complete response rate (82%) to HPPH‐PDT at MTD. HPPH‐PDT can be safely used to treat early‐stage laryngeal cancer, with potential efficacy. © 2015 The Authors Head & Neck Published by Wiley Periodicals, Inc. Head Neck 38: E377–E383, 2016
登录
查看更多内容
影响因子：
2.4
作者：
Nava, Hector R.;Allamaneni, Shyam S.;Dougherty, Thomas J.;Cooper, Michele T.;Tan, Wei;Wilding, Gregory;Henderson, Barbara W.
通讯作者：
Henderson, Barbara W.
DOI：
10.1158/1078-0432.ccr-13-1735
发表时间：
2013-12-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Rigual N;Shafirstein G;Cooper MT;Baumann H;Bellnier DA;Sunar U;Tracy EC;Rohrbach DJ;Wilding G;Tan W;Sullivan M;Merzianu M;Henderson BW
通讯作者：
Henderson BW
影响因子：
2.2
作者：
Silbergleit, Alice K.;Somers, Melissa L.;Peterson, Ed
通讯作者：
Peterson, Ed
影响因子：
7.8
作者：
Rigual, Nestor R.;Shafirstein, Gal;Frustino, Jennifer;Seshadri, Mukund;Cooper, Michele;Wilding, Gregory;Sullivan, Maureen A.;Henderson, Barbara
通讯作者：
Henderson, Barbara
影响因子：
2.3
作者：
Angel, Doug;Doyle, Philip C.;Fung, Kevin
通讯作者：
Fung, Kevin